Skip to main content

Table 2 Response to ATG-based IST at 3, 6, and 9 months

From: Apolipoprotein-A is a potential prognostic biomarker for severe aplastic anemia patients treated with ATG-based immunosuppressive therapy: a single-center retrospective study

Response (n, %)

3-month (n = 61)

6-month (n = 61)

9-month (n = 61)

Complete response (CR)

4 (6.6)

9 (14.8)

14 (23.0)

Partial response (PR)

11 (18.0)

23 (37.7)

26 (42.6)

Overall response (OR)

15 (24.6)

32 (52.5)

40(65.6)

None response (NR)

46 (75.4)

29 (47.5)

21 (34.4)